/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We refer to ACRE together with our consolidated subsidiaries as we, us, Company, or our, unless we specifically state otherwise or the context indicates otherwise. We refer to our manager, Ares Commercial Real Estate Management LLC, as our Manager or ACREM, and the parent company of our Manager, Ares Management Corporation, together with its consolidated subsidiaries, as Ares Management.
$4.72
$0.04 (-0.84%)
EOD Aug 14, 2026
Revenue declined 17.2% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 40% versus the prior year, cash generation momentum has weakened. Net debt of $919M represents 43.0x FCF, leverage limits flexibility.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$35M
▼ -17.2% YoY
Net Income (TTM)
-$4M
▲ +97.4% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
$15M
▼ -39.9% YoY
Op. Cash Flow (TTM)
$15M
▼ -39.9% YoY
Net Debt
$1.16B
Cash & Equiv.
$18M
5Y CAGR: +3.1%
5Y CAGR: -7.6%
Continue Research
SourceComputed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.
Price from market data, last close as of 14 Aug 2026. Sector medians are approximate S&P 500 benchmarks and update periodically.
Ares Commercial Real Estate (ACRE) trades above a two-stage DCF intrinsic value of about $-15.77 per share, so at $4.72 the stock looks overvalued (434.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ares Commercial Real Estate scores 15/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 12.6%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $-15.77 per share for ACRE, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $-11.83. At today's $4.72, that puts the stock about 434.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Ares Commercial Real Estate scores 15 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Ares Commercial Real Estate pays a regular dividend of about $0.60 per share per year (typically in quarterly installments), a yield of roughly 12.6% at the current price. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ACRE's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. ACRE currently trades above its estimated intrinsic value and scores 15/100 on quality (lower-quality). It also yields about 12.6%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.